Specifically, retatrutide simultaneously activates three incretin and metabolic hormone receptors: GLP-1 (glucagon-like peptide-1) receptor promotes insulin secretion, reduces appetite, and slows gastric emptying [8] [9] GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin release and may support fat metabolism [11] [12] Glucagon receptor preclinical and early clinical data suggest this may increase energy expenditure and promote hepatic fat breakdown, though glucagon receptor agonism can also raise blood glucose levels and the full implications in humans are still being characterised [5] [6] This triple mechanism of action is hypothesised to produce meaningful reductions in body weight by addressing multiple aspects of metabolic dysfunction
Interestingly, beyond sensitivity and internalization effects, no immediate modification of 5-HT 2C signaling occurs in any of these situations (Schellekens et al., 2013)
Muri, J., Thut, H., Bornkamm, G
The PlexusDx Precision Peptide Genetic Test examines 14 metabolic pathways and 49 peptides, including variants in GLP1R and FTO genes that influence how quickly your body mobilizes fat and mounts inflammatory responses